CHEK2 and breast carcinoma: For this purpose, here we have tested the prevalence of CHEK2 p.(Asp438Tyr) in breast cancer patients with the indication of hereditary disease susceptibility and those unselected for the family history of cancer and age at disease onset, all collected from the North Ostrobothnia area.